ArticleBiochemical genetics2026
Matrine Alleviates Atherosclerosis by Targeting REG1A and Activating the PI3K/AKT/mTOR Pathway to Inhibit Endothelial Cell Ferroptosis.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cell-Type-Specific Regulation of Ferroptosis in Atherosclerosis: Mechanisms and Therapeutic Potential of Natural Products.Cell biochemistry and function · 2026Review
- Programmed Cell Death of Endothelial Cells in Ischemic Heart Disease: Mechanism and Potential Cell and Gene Therapeutic Prospects.Bioengineering (Basel, Switzerland) · 2026Review
- Matrine as a multi-disease regulator of ferroptosis: mechanisms, therapeutic applications, and toxicity management.Frontiers in pharmacology · 2026Review
- PI3K/AKT signaling pathway: new strategies for treating atherosclerosis with plant-derived compounds.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrine, a natural alkaloid, has a wide range of pharmacological effects, such as antibacterial, anti-inflammatory, anti-oxidation, and anti-tumor. However, the molecular mechanism of matrine in the treatment of atherosclerosis (AS) is not fully understood. Human umbilical vein endothelial cells (HUVECs) were treated with 100 μg/mL ox-LDL to construct an AS cell model in vitro, and the cells were treated with matrine at different concentrations. Our results showed that matrine alleviated the decrease of HUVEC viability and the increase of ferroptosis induced by ox-LDL treatment. Subsequently, we found that matrine targeted regenerating family member 1 alpha (REG1A) and inhibited the expression level of REG1A in ox-LDL treated HUVECs. Overexpression of REG1A attenuated the improvement of matrine on activation of the PI3K/Akt/mTOR pathway and ferroptosis in ox-LDL treated HUVECs. In addition, both LY294002 (an inhibitor of the PI3K signaling) and Erastin (an inducer of ferroptosis) reversed the alleviation of matrine treatment on ferroptosis in ox-LDL treated HUVECs. The results in vivo showed that matrine treatment inhibited high-fat diet-induced aortic ferroptosis in ApoE
Indexed as
Identifiers
40281246What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.